Bioequivalence Margins Do Not Need Revision For All Generics, Panel Says
Executive Summary
While narrower bioequivalence margins might be necessary for certain categories of generic drugs, FDA's Pharmaceutical Science and Clinical Pharmacology Advisory Committee has determined that the specifications should not be tightened across the board for all generic drug approvals